Treatment and Outcomes of Children and Adults With Rhabdomyosarcoma in Rwanda
Pediatric Blood & Cancer · 2026-04 · 73 (4)
DOI: 10.1002/1545-5017.70126 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, online erschienen am 12.01.2026. Verfasst von Oscar Nsanzimana und 14 weiteren Autor:innen. Beteiligte Einrichtung: Partners in Health/Inshuti Mu Buzima, Kigali, Rwanda. Hauptthemen laut MEDLINE: Rhabdomyosarcoma, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma affecting children and young adults, but few reports describe its presentation and outcomes in Africa. Procedure We conducted a retrospective chart review of patients of all ages with RMS presenting to the Butaro Cancer Center of Excellence in Rwanda between July 2012 and June 2022.
Results
Fifty‐nine patients with histopathologically confirmed RMS were treated using Intergroup RMS Study Group protocols adapted to the local context. Median age was 9.1 years (interquartile range [IQR] 3.5–16.6); 54.2% were female. Median duration from symptom onset to presentation was 5 months (IQR 4–7). Most had embryonal histology (66.1%), followed by alveolar (20.3%), pleomorphic (6.8%), and anaplastic (1.7%). At presentation, 16 patients (27.1%) had stage I, 3 (5.1%) had stage II, 22 (37.3%) had stage III, and 14 (23.7%) had stage IV disease; 4 (6.8%) were unstaged. Of the 39 patients treated with curative intent, 25 (64.1%) received local control and 16 (41.0%) completed all planned therapy. Two‐year event‐free survival was 23.3% (95% CI 13.5%–34.8%, n = 55) overall and 61.4% (95% CI 33.3%–80.5%, n = 16) among those who completed treatment.
Conclusions
Treatment of RMS in a rural district hospital is feasible. Although outcomes remain lower than in high‐income countries, survival was markedly higher in patients who completed therapy. Future efforts should focus on earlier diagnosis and support for timely transitions between specialties with the goal of optimizing completion of planned care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Partners in Health/Inshuti Mu Buzima, Kigali, Rwanda.
- University of Global Health Equity, Kigali, Rwanda.
- Butaro Level 2 Teaching Hospital, Butaro, Rwanda.
- Boston Children's Hospital, Boston, Massachusetts, USA.
- Alaska Native Medical Center, Anchorage, Alaska, USA.
- University of Colorado, Aurora, Colorado, USA.
ORCID-Profile: Oscar Nsanzimana, David S Shulman
Zitieren
APA
Nsanzimana, O., Carpenter, K., Villaverde, C., Shyirambere, C., Mujyuwisha, L., Fehr, A., Nguyen, C., Uwamahoro, P., Iradukunda, E., Nsabimana, V., Ruhangaza, D., Ntaganda, E., Shulman, L. N., Shulman, D. S., & Lehmann, L. (2026). Treatment and Outcomes of Children and Adults With Rhabdomyosarcoma in Rwanda. Pediatric Blood & Cancer, 73(4). https://doi.org/10.1002/1545-5017.70126
Vancouver
Nsanzimana O, Carpenter K, Villaverde C, Shyirambere C, Mujyuwisha L, Fehr A, et al. Treatment and Outcomes of Children and Adults With Rhabdomyosarcoma in Rwanda. Pediatric Blood & Cancer. 2026;73(4). doi:10.1002/1545-5017.70126
BibTeX
@article{Nsanzimana2026,
author = {Nsanzimana, Oscar and Carpenter, Kendall and Villaverde, Chandler and Shyirambere, Cyprien and Mujyuwisha, Louis and Fehr, Alexandra and Nguyen, Cam and Uwamahoro, Pacifique and Iradukunda, Esperance and Nsabimana, Vivens and Ruhangaza, Deogratias and Ntaganda, Edmond and Shulman, Lawrence N and Shulman, David S and Lehmann, Leslie},
title = {Treatment and Outcomes of Children and Adults With Rhabdomyosarcoma in Rwanda},
journal = {Pediatric Blood & Cancer},
year = {2026},
volume = {73},
number = {4},
doi = {10.1002/1545-5017.70126}
}
EUVIMED